40.40
+1.61(+4.15%)
Currency In USD
| Previous Close | 38.79 |
| Open | 38.51 |
| Day High | 40.61 |
| Day Low | 38.51 |
| 52-Week High | 62.53 |
| 52-Week Low | 35.51 |
| Volume | 672,367 |
| Average Volume | 851,506 |
| Market Cap | 3.75B |
| PE | -10.92 |
| EPS | -3.7 |
| Moving Average 50 Days | 49.53 |
| Moving Average 200 Days | 50.53 |
| Change | 1.61 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,648.31 as of February 05, 2025 at a share price of $40.4. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $1,768.83 as of February 05, 2025 at a share price of $40.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jan 10, 2025 10:15 PM GMT
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggr
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
GlobeNewswire Inc.
Jan 10, 2025 12:00 PM GMT
Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH A
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2025 1:00 PM GMT
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43rd Annual J.P. Morgan Healthcare Confer